Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 Jul;167(7):763-72.
doi: 10.1176/appi.ajp.2009.09040598. Epub 2010 Mar 1.

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis

Jian-Ping Zhang  1 , Todd Lencz, Anil K Malhotra
Affiliations
Meta-Analysis

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis

Jian-Ping Zhang et al. Am J Psychiatry. 2010 Jul.

Abstract

Objective: Several lines of evidence suggest that antipsychotic drug efficacy is mediated by dopamine type 2 (D(2)) receptor blockade. Therefore, it seems plausible that variation in the DRD(2) gene is associated with clinical response to antipsychotic drug treatment. The authors conducted the first meta-analysis to examine the relationship between DRD2 polymorphisms and antipsychotic drug response.

Method: A MEDLINE search of articles available up to December 31, 2008, yielded 18 prospective studies examining DRD2 gene variation and antipsychotic response in schizophrenia patients; of which, 10 independent studies met criteria for inclusion. Clinical response to antipsychotic treatment was defined as a 50% reduction of either the Brief Psychiatric Rating Scale total score or Positive and Negative Syndrome Scale total score at approximately 8 weeks of follow-up evaluation. Odds ratio was the primary effect-size measure and computed for each polymorphism in each study. Sufficient data were available for two DRD2 polymorphisms: -141C Ins/Del and Taq1A.

Results: Six studies reported results for the -141C Ins/Del polymorphism (total sample size: N=687). The Del allele carrier was significantly associated with poorer antipsychotic drug response relative to the Ins/Ins genotype. Eight studies assessed the Taq1A polymorphism and antipsychotic response (total sample size: N=748). There was no significant difference in the response rate among A1 allele carriers relative to individuals with the A2/A2 genotype or A2 allele carriers relative to individuals with the A1/A1 genotype.

Conclusions: The DRD2 genetic variation is associated with clinical response to antipsychotic drug treatment. These data may provide proof-of-principle for pharmacogenetic studies in schizophrenia.

PubMed Disclaimer

Conflict of interest statement

Disclosures of Conflict of Interest: Dr. Malhotra is a consultant/advisor to Eli Lilly, Janssen, Wyeth, Vanda, and a member of the Speakers Bureau for BMS. Dr. Lencz is a consultant to Eli Lilly.

Figures

Figure 1
Figure 1
Location of the Taq1A and -141C Ins/Del polymorphisms in the context of ANKK1 and DRD2 at chromosome 11q22. Red triangles represent areas of high linkage equilibrium (D′).
Figure 2
Figure 2
Flow chart of literature search.
Figure 3
Figure 3
Meta-analysis of the association between the -141C Ins/Del polymorphism (Del carrier vs. Ins/Ins) and antipsychotic drug response: Forrest plot and funnel plot. Note: M-H: Mantel-Haenszel method.
Figure 4
Figure 4
Meta-analysis of the association between the Taq1A polymorphism and antipsychotic drug response: Forrest plot and funnel plot. (a) A1/A1 vs. A2 carrier; (b) A1 carrier vs. A2/A2. Note: M-H: Mantel-Haenszel method.
Figure 4
Figure 4
Meta-analysis of the association between the Taq1A polymorphism and antipsychotic drug response: Forrest plot and funnel plot. (a) A1/A1 vs. A2 carrier; (b) A1 carrier vs. A2/A2. Note: M-H: Mantel-Haenszel method.
See this image and copyright information in PMC

References

    1. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46(10):1396–408. - PubMed
    1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23. - PubMed
    1. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry. 2006;63(10):1079–87. - PubMed
    1. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–97. - PubMed
    1. Malhotra AK, Murphy GM, Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161(5):780–96. - PubMed

Publication types

Substances

LinkOut - more resources